Alexion Strikes Development Deal With Caelum Biosciences in Rare Systemic Disorder

Shares of Fortress Biotech have skyrocketed more than 62 percent in premarket trading after its subsidiary Caelum Biosciences forged a deal worth up to more than $500 million with Alexion Pharmaceuticals.